Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Debt (2016 - 2026)

Amphastar Pharmaceuticals has reported Total Debt over the past 13 years, most recently at $610.4 million for Q4 2025.

  • For Q4 2025, Total Debt rose 1.42% year-over-year to $610.4 million; the TTM value through Dec 2025 reached $610.4 million, up 1.42%, while the annual FY2025 figure was $610.4 million, 1.42% up from the prior year.
  • Total Debt for Q4 2025 was $610.4 million at Amphastar Pharmaceuticals, roughly flat from $609.5 million in the prior quarter.
  • Over five years, Total Debt peaked at $638.6 million in Q3 2023 and troughed at $38.5 million in Q2 2021.
  • A 5-year average of $358.0 million and a median of $544.2 million in 2023 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: decreased 7.02% in 2021 and later soared 743.74% in 2023.
  • Year by year, Total Debt stood at $77.0 million in 2021, then decreased by 1.42% to $75.9 million in 2022, then soared by 677.51% to $590.0 million in 2023, then increased by 2.01% to $601.9 million in 2024, then grew by 1.42% to $610.4 million in 2025.
  • Business Quant data shows Total Debt for AMPH at $610.4 million in Q4 2025, $609.5 million in Q3 2025, and $608.7 million in Q2 2025.